Literature DB >> 19038756

Lung cancer: moving forward with tailored strategies.

Fabrice Barlesi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19038756     DOI： 10.1016/S1470-2045(08)70290-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

Review 1.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

2.  A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.

Authors:  Xavier Elharrar; Dominique Barbolosi; Joseph Ciccolini; Christophe Meille; Christian Faivre; Bruno Lacarelle; Nicolas André; Fabrice Barlesi
Journal:  BMC Cancer       Date:  2016-04-20       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.